New Discovery Holds Promise for Long COVID Treatments
Researchers at the University of Alberta Uncover Markers for Identifying Long COVID Patients
Researchers at the University of Alberta have made a significant breakthrough in understanding long COVID, a stubborn condition that affects millions of people globally. The team has identified two proteins that could serve as markers for identifying patients with long COVID. This discovery opens the door to potential treatments that could improve the quality of life for those with debilitating symptoms.
Understanding Long COVID Symptoms and patients
Long COVID is characterized by symptoms like chronic fatigue, intense pain, difficulty breathing, sleep problems, cardiovascular issues, and cognitive problems, often referred to as “brain fog.” This condition can persist for months or even years in about 10% of people who contract SARS-CoV-2. Contrary to popular belief, a severe initial infection may not necessarily lead to long COVID. In fact, long COVID often arises from mild infections that do not require intensive care.
Key Findings by Research Team
Led by immunologist Shokrollah Elahi, the research team conducted two studies involving 78 patients with severe long COVID symptoms and 58 fully recovered people. The studies helped them identify key differences in immune cells and protein markers between these groups.
Elevated Inflammation and Immune Suppression
One of the major findings was that patients with long COVID exhibited higher levels of inflammatory cells called neutrophils and monocytes, and fewer protective lymphocytes. Moreover, these patients had more exhausted killer T cells, a vital part of the immune system’s defense against infections. This indicates persistent inflammation and immune dysregulation, providing critical insights into the condition’s underlying causes.
Immature Red Blood Cells and Protein Markers
The study also revealed that long COVID affects the production of red blood cells, leading to an abundance of immature cells in the blood of patients. These immature red blood cells can suppress the immune system and elevate proteins like artemin in the plasma. This discovery underscores the intricate link between gut health and systemic inflammation in long COVID patients.
Potential Treatment for Long COVID
Elahi attributes the chronic inflammation common in long COVID patients to proteins like galectin-9 and artemin. Initial observations suggest that gastrointestinal issues, such as diarrhea, may trigger long COVID. Damaged intestinal tissues and gut leakiness are potential drivers of chronic inflammation and are treatable with available medications.
Multi-disciplinary Collaboration and Patient Involvement
The collaborative efforts of clinicians and researchers, supported by patient organizations, contributed significantly to this breakthrough. Dr. Mo Osman and his team at the University of Alberta Hospital played a crucial role in patient recruitment and clinical assessment. The findings underscore the importance of multi-disciplinary approaches and community involvement in advancing medical research.
Funding and Future Directions
The research was funded by the Canadian Institutes of Health Research (CIHR) and supported by the Li Ka Shing Institute of Virology at the University of Alberta. Continued research and investment are crucial for bringing these findings from the lab to the bedside, addressing the urgent needs of long COVID patients.
Call to Action
If you or someone you know is suffering from long COVID symptoms, exploring these findings and their potential treatments is vital. Join organizations supporting long COVID research and rate the symptoms to contribute to ongoing studies. Stay informed about the latest advancements aimed at improving the lives of those affected by this debilitating condition.
